Rozlytrek Entrectinib NTRK ROS1 Fusion Solid Tumors Review 2026
Author: Critical Kare PharmaMolecular Oncology Desk
On October 29, 2026, clinical oncology panels reviewed Rozlytrek® (Entrectinib 200 mg and 100 mg hard capsules) developed by Genentech / Roche for NTRK fusion-positive solid tumors and ROS1-positive non-small cell lung cancer.
Rozlytrek features specialized blood-brain barrier penetrance, demonstrating high intracranial activity in patients with baseline brain metastases across both ROS1-rearranged NSCLC and NTRK-positive solid tumors.
Through Critical Kare Pharma, certified genuine packs of Rozlytrek Entrectinib Capsules are supplied directly to practicing oncologists and hospital pharmacies internationally.
Pharmacodynamics & Central Nervous System Penetration
- Multi-Kinase Targeting: Potent inhibitor of TRK A/B/C, ROS1, and ALK kinases, with design optimized for retention within the central nervous system.
- STARTRK-2 Trial: Intracranial response rate of 55% in ROS1-positive NSCLC patients with CNS lesions, with prolonged median intracranial PFS.
- Dosing Protocol: 600 mg orally once daily with or without food for adults; dose reductions to 400 mg or 200 mg for adverse reactions.
International Procurement
Facilitated under official import waivers across the US, UK, European Union, Australia, and GCC nations via Critical Kare Pharma.
